NCT00244764 - GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma | Biotech Hunter

Enrollment

225

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

March 31, 2008

Study Completion Date

September 30, 2013

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

GW786034

All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.

DRUG

Placebo

Trial Locations (45)

100

GSK Investigational Site, Taipei

1070

GSK Investigational Site, Brussels

1090

GSK Investigational Site, Jette

1200

GSK Investigational Site, Brussels

2031

GSK Investigational Site, Randwick

2050

GSK Investigational Site, Camperdown

2217

GSK Investigational Site, Kogarah

2610

GSK Investigational Site, Wilrijk

3002

GSK Investigational Site, East Melbourne

3011

GSK Investigational Site, Footscay

3050

GSK Investigational Site, Parkville

3084

GSK Investigational Site, Heidelberg

4000

GSK Investigational Site, Liège

8800

GSK Investigational Site, Roeselare

9000

GSK Investigational Site, Ghent

12808

GSK Investigational Site, Prague

30084

GSK Investigational Site, Tucker

31096

GSK Investigational Site, Haifa

37203

GSK Investigational Site, Nashville

44106

GSK Investigational Site, Cleveland

44195

GSK Investigational Site, Cleveland

46202

GSK Investigational Site, Indianapolis

49100

GSK Investigational Site, Petah Tikva

64239

GSK Investigational Site, Tel Aviv

70300

GSK Investigational Site, Zrifin

75246

GSK Investigational Site, Dallas

80010

GSK Investigational Site, Aurora

90095

GSK Investigational Site, Los Angeles

92868

GSK Investigational Site, Orange

94115

GSK Investigational Site, San Francisco

100034

GSK Investigational Site, Beijing

100853

GSK Investigational Site, Beijing

200040

GSK Investigational Site, Shanghai

210029

GSK Investigational Site, Nanjing

250012

GSK Investigational Site, Jinan

310003

GSK Investigational Site, Hangzhou

510060

GSK Investigational Site, Guangzhou

91010-3000

GSK Investigational Site, Duarte

10032-3713

GSK Investigational Site, New York

656 53

GSK Investigational Site, Brno

500 05

GSK Investigational Site, Hradec Králové

Unknown

GSK Investigational Site, Hong Kong

GSK Investigational Site, Kowloon

GSK Investigational Site, Tuenmen

GSK Investigational Site, Taipei